vVARDIS Lands Apollo Investment, Tops $1 Billion Valuation on Curodont Expansion

1 articles · Updated · Market.us · Jun 22

Apollo-managed funds made a strategic minority investment in vVARDIS, lifting the Swiss dental company into the ranks of privately held healthcare businesses valued at more than $1 billion.
The deal is aimed at expanding vVARDIS's Curodont technology suite, its drill-free early tooth decay treatment platform that the company is rolling out globally.
vVARDIS had already raised $50 million in July 2025, bringing total financing at that point to $85 million from OrbiMed to support Curodont's expansion.
The investment comes as oral hygiene demand is projected to grow from $38.7 billion in 2025 to $70.7 billion by 2035, with preventive and clinically backed products drawing increasing investor interest.

Sources

With smart toothbrushes and single-use sachets, is the oral care market splitting into two separate worlds?

As oral care becomes medicalized, will your dentist soon prescribe your toothpaste?

Your mouth's bacteria are linked to cancer; what new science can rebalance your oral microbiome?

1 total